Coronary Intervention Without a Safety Net

Journal of the American College of Cardiology

Volumn 52, Issue 16, 2008, Pages 1299-1301

  Dauerman, Harold L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

bleeding; percutaneous coronary intervention; pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; EDITORIAL; HIGH RISK PATIENT; HUMAN; INTRAVASCULAR ULTRASOUND; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THROMBUS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY STENOSIS; FEMALE; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, ELECTIVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 53049109334     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.024     Document Type: Editorial

References (22)

1. DeMaria A.N. Clinical trials and clinical judgment. J Am Coll Cardiol 51 (2008) 1120-1122
2. Stabile E., Nammas W., Salemme L., et al. The CIAO (Coronary Interventions Antiplatelet-based Only) study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 52 (2008) 1293-1298
3. de Feyter P.J., Ozaki Y., Baptista J., et al. Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation 92 (1995) 1408-1413
4. Hong M.K., Mintz G.S., Lee C.W., et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circulation 110 (2004) 928-933
5. Yusuf S., Mehta S.R., Chrolavicius S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
6. Buller C.E., Pate G.E., Armstrong P.W., et al. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. Can J Cardiol 22 (2006) 511-515
7. Hopp H.W., Karabacak S., Stoll R., Karasch T., and Franzen D. Intracoronary thrombi in stable angina: observations with angioscopy. Catheter Cardiovasc Interv 51 (2000) 18-19
8. Mintz G.S., Maehara A., Bui A.B., and Weissman N.J. Multiple versus single coronary plaque ruptures detected by intravascular ultrasound in stable and unstable angina pectoris and in acute myocardial infarction. Am J Cardiol 91 (2003) 1333-1335
9. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation 99 (1999) 44-52
10. Aggarwal A., Schneider D.J., Terrien E.F., Terrien Jr. C.M., Sobel B.E., and Dauerman H.L. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 91 (2003) 1346-1349
11. DeNardo S.J., Davis K.E., and Tcheng J.E. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 149 (2005) 138-144
12. Valencia R., Price M.J., Sawhney N., et al. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial). Am J Cardiol 100 (2007) 1099-1102
13. Chew D.P., Bhatt D.L., Lincoff A.M., et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 103 (2001) 961-966
14. Brener S.J., Moliterno D.J., Lincoff A.M., Steinhubl S.R., Wolski K.E., and Topol E.J. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 110 (2004) 994-998
15. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
16. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
17. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
18. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358 (2008) 2457-2467
19. Bittl J.A., Chaitman B.R., Feit F., Kimball W., and Topol E.J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142 (2001) 952-959
20. Dauerman H.L. Percutaneous coronary intervention pharmacology: from a triangle to a square. J Am Coll Cardiol 51 (2008) 698-700
21. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
22. Gogo Jr. P.B., Dauerman H.L., Mulgund J., et al. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE quality improvement initiative). Am J Cardiol 99 (2007) 1222-1226